RxDoctor Payments Data

James Flaherty, DO

Urogynecology and Reconstructive Pelvic Surgery · The Villages, FLNPI 1639148331

Payments from drug & device makers

$1,551in general payments, 2019–2025

Across 45 payments — averaging $34.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$711
  • AbbVie$174
  • Amgen$96
  • Sumitomo Pharma America, Inc.$96
  • Astellas Pharma US Inc$79
  • Pfizer$67
  • plus $328 from 11 others

What the payments were for

  • Travel & lodging$71146%
  • Food & beverage$84054%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,551 in reported general payments places this provider in the 15th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$49,407
Medicare patients
117
Services billed
1,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron206$184,780
MyrbetriqMirabegron100$103,271
Estradiol224$15,845
PremarinEstrogens, Conjugated20$8,948
ImvexxyEstradiol12$4,979
Desmopressin Acetate37$2,929
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst52$1,243
Metronidazole18$899
ProgesteroneProgesterone, Micronized35$774
Trimethoprim15$523
Fluconazole13$98
Triamcinolone Acetonide13$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$96$184,780206 claims
Astellas Pharma US IncMyrbetriq$79$103,271100 claims
PfizerPremarin$67$8,94820 claims
Therapeuticsmd, Inc.Imvexxy$35$4,97912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

Other urogynecology and reconstructive pelvic surgery in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →